Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease

被引:49
|
作者
Wilson, Andrew M. [1 ]
Shin, David S. [1 ]
Weatherby, Carlton [1 ]
Harada, Randall K. [1 ]
Ng, Martin K. [1 ]
Nair, Nandini [1 ]
Kielstein, Jan [1 ]
Cooke, John P. [1 ]
机构
[1] Stanford Univ, Med Ctr, Falk Cardiovasc Res Inst, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
asymmetric dimethylarginine; atherosclerosis; nitric oxide; peripheral arterial disease; prognosis; ACUTE MYOCARDIAL-INFARCTION; L-ARGININE SUPPLEMENTATION; OXIDE SYNTHASE INHIBITOR; NITRIC-OXIDE; ENDOTHELIAL DYSFUNCTION; VASCULAR-DISEASE; OCCLUSIVE DISEASE; MEDICAL-TREATMENT; RISK-FACTOR; DIMETHYLAMINOHYDROLASE;
D O I
10.1177/1358863X10364552
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Peripheral arterial disease (PAD) is associated with major cardiovascular morbidity and mortality. Abnormalities in nitric oxide metabolism due to excess of the NO synthase inhibitor asymmetric dimethylarginine (ADMA) may be pathogenic in PAD. We explored the association between ADMA levels and markers of atherosclerosis, function, and prognosis. A total of 133 patients with symptomatic PAD were enrolled. Ankle-brachial index (ABI), walking time, vascular function measures (arterial compliance and flow-mediated vasodilatation) and plasma ADMA level were assessed for each patient at baseline. ADMA correlated inversely with ABI (r = -0.238, p = 0.003) and walking time (r = -0.255, p = 0.001), independent of other vascular risk factors. We followed up 125 (94%) of our 133 initial subjects with baseline measurements (mean 35 months). Subjects with ADMA levels in the highest quartile (> 0.84 mu mol/l) showed a significantly greater occurrence of a major adverse cardiovascular event (MACE) compared to those with ADMA levels in the lower three quartiles (p = 0.001). Cox proportional-hazards regression analysis revealed that ADMA was a significant predictor of MACE, independent of other risk factors including age, sex, blood pressure, smoking history, diabetes and ABI (hazard ratio = 5.1, p < 0.001). Measures of vascular function, such as compliance, flow-mediated vasodilatation (FMVD) and blood pressure, as well as markers of PAD severity, including ABI and walking time, were not predictive. In conclusion, circulating levels of ADMA correlate independently with measures of disease severity and major adverse cardiovascular events. Agents that target this pathway may be useful for this patient population. Clinical Trial Registration - URL: http:// www.clinicaltrials.gov. Unique identifier: NCT00284076.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 50 条
  • [21] Continuous aspirin treatment improves cardiovascular events and all-cause mortality in hemodialysis patients with peripheral artery disease
    Wu, Chung-Kuan
    Yar, Noi
    Chen, Yun-Yi
    RENAL FAILURE, 2024, 46 (02)
  • [22] Doubled risk of all-cause and cardiovascular death in elderly patients with peripheral arterial disease
    Diehm, C.
    Trampisch, H. J.
    Haberl, R. L.
    Mahn, M.
    Pittrow, D.
    Tepohl, G.
    Allenberg, J. R.
    Burghaus, I.
    Darius, H.
    EUROPEAN HEART JOURNAL, 2008, 29 : 787 - 787
  • [23] Risk Factor Control and Major Adverse Cardiovascular Events in Patients With Peripheral Arterial Disease
    Parvar, Saman L.
    Nicholls, Stephen J.
    Lincoff, A. M.
    Menon, Venu
    Riesmeyer, Jeffrey S.
    Ruotolo, Giacomo
    Wolski, Kathy
    McErlean, Ellen
    Nissen, Steven E.
    CIRCULATION, 2017, 136
  • [24] Effect of Ezetimibe on Major Atherosclerotic Disease Events and All-Cause Mortality
    Hayek, Sami
    Escaro, Fabrizio Canepa
    Sattar, Assad
    Gamalski, Steven
    Wells, Karen E.
    Divine, George
    Ahmedani, Brian K.
    Lanfear, David E.
    Pladevall, Manel
    Williams, L. Keoki
    AMERICAN JOURNAL OF CARDIOLOGY, 2013, 111 (04): : 532 - 539
  • [25] MAJOR CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY AFTER KIDNEY TRANSPLANTATION IN DIABETIC PATIENTS WITH PRE-EXISTING CORONARY ARTERY DISEASE OR PERIPHERAL VASCULAR DISEASE
    Jiwani, Sania Pyarali
    Chan, Wan-Chi
    Majmundar, Monil M.
    Mehta, Harsh
    Yarlagadda, Sri G.
    Gupta, Aditi
    Hockstad, Eric
    Wiley, Mark
    Tadros, Peter N.
    Gupta, Kamal
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 1259 - 1259
  • [26] Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease
    Lee, Da Young
    Moon, Jun Sung
    Jung, Inha
    Chung, Seung Min
    Park, So Young
    Yu, Ji Hee
    Seo, Ji A.
    Han, Kyung-do
    Kim, Nan Hee
    DIABETES OBESITY & METABOLISM, 2025, 27 (03): : 1554 - 1563
  • [27] Association of major adverse cardiovascular events and all-cause mortality with left ventricular geometry in elderly
    Maimaitiaili, R.
    Zhao, S.
    Xu, C.
    Meng, W.
    Tang, J.
    Yang, H.
    Teliewubai, J.
    Yu, S.
    Chi, C.
    Xiong, J.
    Zhao, Y.
    Xu, Y.
    Zhang, Y.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [28] Relation of Adiponectin to All-Cause Mortality, Cardiovascular Mortality, and Major Adverse Cardiovascular Events (from the Dallas Heart Study)
    Witberg, Guy
    Ayers, Colby R.
    Turer, Aslan T.
    Lev, Eli
    Kornowski, Ran
    de Lemos, James
    Neeland, Ian J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2016, 117 (04): : 574 - 579
  • [29] Severity of Diabetic Retinopathy and the Risk of Future Cerebrovascular Disease, Cardiovascular Disease, and All-Cause Mortality
    Modjtahedi, Bobeck S.
    Wu, Jun
    Luong, Tiffany Q.
    Gandhi, Nainesh K.
    Fong, Donald S.
    Chen, Wansu
    OPHTHALMOLOGY, 2021, 128 (08) : 1169 - 1179
  • [30] Retinopathy, neuropathy and peripheral arterial disease as independent predictors of all-cause mortality
    Tapp, Robyn
    Zimmet, Paul
    Harper, C. Alex
    Dunstan, David
    Barr, Elizabeth
    Tonkin, Andrew
    Welborn, Timothy
    Taylor, Hugh
    Shaw, Jonathan
    DIABETES, 2006, 55 : A229 - A229